Parenteral nutrition and injectables dialysis
Parenteral nutrition and intravenous injection are applications requiring products of the highest standards of quality. Our products are manufactured with the same care, control and attention to detail at every stage of the process, and we have invested heavily to ensure all pharmaceutical grade products are all produced in line with appropriate quality management systems. Our ingredients for parenteral applications provide many functionalities including: energy source, osmotic agent, osmotic diuretic, emulsification and solubilization.
The phospholipid phosphatidylcholine has also proven in many studies to have advantageous effects on the liver, even if it has been impaired.*
* All potential health claims are currently subject to final approval by the EFSA.
Energy source for parenteral nutrition
Nutrition is a significant factor in considering ingredients for parenteral applications – a sufficient supply of energy in the immediate post-traumatic or post-operative recovery phase is particularly important for patients.
We manufacture pyrogen-free monohydrous dextrose under the name C* PharmDex™, which meets the highest purity standards. This is achieved by ultrafiltration techniques that prevent endotoxin (pyrogen) contamination and remove any occurring polysaccharides. C* PharmDex™ is ideally suited to parenteral nutrition – it is readily water soluble, is very stable and its and solutions are characterized by excellent filterability. Also available is endotoxin-free mannitol, a reduced calorie nutrient that is used in dialysis and serum applications.
|Monohydrous dextrose||C* PharmDex™|
Emulsifying agents for parenteral nutrition
Cargill’s phospholipids are excellent emulsifiers for parenteral nutrition and contribute additionally to the energy delivered to the patient.
|Deoiled phospholipid||Epikuron™ 145 V*|
|Purified phospholipid||Epikuron™ 170*|
|Purified phosphatidylcholine||Epikuron™ 200*|
* The product serves also as choline source, protects the liver, controls the level of cholesterol and is a source of polyunsaturated fatty acids.
N.B. All potential health claims are currently subject to final approval by the EFSA.
Osmotic agents in injectables and dialysis
The aim of intravenous treatments is to optimize the balance of fluids, energy, nitrogen and electrolytes in the blood by the infusion of appropriate solutions. As with all parenteral applications, ensuring the solution is pyrogen-free is vital.
Our plants operate a dedicated production channel for pharmaceutical-grade dextrose monohydrate and mannitol for intravenous injections. The plant facilities have been audited by most of the producers of solutions of parenteral infusion and hemodialysis worldwide. Cargill was approved as a qualified supplier in all cases.
|Monohydrouse dextrose||C* PharmDex™|